InvestorQ : How will the latest pacts of Biocon to distribute generic products in South East Asia help the stock performance?
Mary Joseph made post

How will the latest pacts of Biocon to distribute generic products in South East Asia help the stock performance?

Answer
user profile image
sara Kunju answered.
4 months ago


Biocon inked a pact DKSH for distribution of 7 generic products across the South Asian markets of Singapore and Thailand. DKSH is a market expansion service provider and helps pharma companies to expand their market in new geographies. This deal was struck by Biocon Pharma, a subsidiary of Biocon.

The terms of the deal stipulate that Biocon’s partner DKSH be granted exclusive license to register and commercialise the 7 generic formulations from therapeutic areas like diabetology, cardiology, oncology and immunology. These medicines will be specifically sold under Biocon's brand in Singapore and Thailand using DKSH networks.

DKSH will be responsible for marketing and sales as well as handling logistics while the Biocon subsidiary, Biocon Pharma, will support DKSH through its capabilities and strengths in the medical and pharmacy channels. This will help patients in this region to access affordable high-quality generics for chronic diseases.

Biocon has a generic formulations pipeline of complex molecules and based on a strong track record of quality and reliability. The deep research capabilities of Biocon are an added advantage. On the other hand, DKSH helps Asian patients get reliable and efficient access to the best healthcare possible, with an emphasis on quality and technology use.